There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Latent TGF-beta 1

Latent TGF-beta 1

Latent TGF-beta 1 Molecule Information

Name:Transforming growth factor beta 1
Target Synonym:TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1,IBDIMDE,Transforming Growth Factor beta1,Latency-Associated Peptide,TGFB,CED,DPD1,Transforming Growth Factor, Beta 1,TGF-Beta-1,Prepro-Transforming Growth Factor Beta-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Latent TGF-beta 1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
Cat. No. Species Product Description Structure Purity Feature
TG1-C5243 Cynomolgus Cynomolgus Latent TGF-beta 1 (C33S) Protein, His Tag
TG1-H82Qb Human Biotinylated Human Latent TGF-Beta 1 / TGFB1 Protein, His,Avitag™
TG1-H524x Human Human Latent TGF-beta 1 / TGFB1 Protein, His Tag

Latent TGF-beta 1 Part of Bioactivity data

TG1-H524x-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) inhibits the IL-4-dependent proliferation of TF-1 cells. The ED50 for this effect is 0.293-0.406 ng/mL (Routinely tested).

Biotinylated Human Latent TGF-Beta 1, His,AvitagBiotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) ELISA bioactivity

Immobilized Human ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-H52E1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 0.5-4 ng/mL (QC tested).

Cynomolgus Latent TGF-Beta 1 (C33S), His TagCynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) ELISA bioactivity

Immobilized Cynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 0.6-20 ng/mL (QC tested).

Latent TGF-beta 1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirfenidone F-647; AMR-69; GP-101; S-7701; S-770108; RO-0220912 Approved Intermune 艾思瑞, Deskar, Etuary, Esbriet, Pirespa, Aisuryui United States Idiopathic Pulmonary Fibrosis s:13:"Genentech Inc"; 2008-10-16 Radiation Pneumonitis; Renal Insufficiency; Dermatomyositis; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Pulmonary Fibrosis; Lung Diseases, Interstitial; Diabetic Nephropathies; Alveolitis, Extrinsic Allergic; Pneumoconiosis Details

Latent TGF-beta 1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
盐酸美氟尼酮 Phase 1 Clinical Guangzhou Nanxin Pharmaceutical Co Ltd, Central South University Diabetic Nephropathies Details
DW-1029M DW-1029M Phase 2 Clinical Dong Wha Pharmaceuticals Diabetic Nephropathies Details
Disitertide P-144; NAFB-001; Peptide-144 Phase 2 Clinical Digna Biotech, University Of Navarra Fibrosis; Scleroderma, Systemic Details
Fluorofenidone AKF-PD Phase 1 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis; Renal fibrosis Details
YL-13027 YL-13027 Phase 1 Clinical Shanghai Yingli Pharmaceutical Co Ltd Solid tumours Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Vactosertib EW-7197; NOV-1301; TEW-7197 Phase 2 Clinical Medpacto Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Urologic Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
STP-705 STP-705; STP-705L; STP-705LU; STP-705LV Phase 2 Clinical Suzhou Shengnuo Biological Medicine Technology Co Ltd, Sirnaomics Liver Neoplasms; Bowen's Disease; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Squamous Cell; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.